Christmas Cheer For Cipla’s Seretide Equivalent In The UK
Executive Summary
Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.
You may also be interested in...
Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.
Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.
Operational Fixes At Cipla But All Eyes On Generic Advair
Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.